CD19 and acute lymphoblastic leukemia: Maude et al. [146] administered pembrolizumab to four patients with r/rB-ALL who had an inadequate response to CD19-targeted CAR-T-cell therapy; although the treatment was successful and resulted in long-term detection of CAR-T cells, it was not durable.